



- (51) **International Patent Classification:**  
A61M 11/00 (2006.01) A61P 31/00 (2006.01)
- (21) **International Application Number:**  
PCT/US2013/043608
- (22) **International Filing Date:**  
31 May 2013 (31.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/654,519 1 June 2012 (01.06.2012) US
- (71) **Applicants:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US/US]; One Gustave L. Levy Place, New York, NY (US). YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT [IL/IL]; The Weizmann Institute Of Science, P.O. Box 95, 7610002 Rehovot (IL). UNIVERSITAT DUISBURG-ESSEN [DE/DE]; Universitätsstrasse 2, 45141 Essen (DE).
- (72) **Inventors:** SCHUCHMAN, Edward, H.; 300 Lakeside Drive, Haworth, NJ 07641 (US). GULBINS, Erich; Ostpreussenstrasse 86, 45259 Essen (DE). FUTERMAN, Anthony; Meonot Brazil 4A, 76100 Rehovot (IL). PEWZNER-JUNG, Yael; Meonot Wolfson B/21, 76100 Rehovot (IL).
- (74) **Agents:** GOLDMAN, Michael, L. et al.; LeClairRyan, 70 Linden Oaks, Suite 210, Rochester, NY 14625 (US).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- Published:**
- with international search report (Art. 21(3))
  - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** CERAMIDE LEVELS IN THE TREATMENT AND PREVENTION OF INFECTIONS




FIGURE 3

(57) **Abstract:** The present invention relates to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection. The method also involves the use of a ceramidase in combination with other drugs to reduce infection, reduce ceramide, or improve lung function in Cystic Fibrosis, COPD, and/or open wound patients.

WO 2013/181530 A1

## CERAMIDE LEVELS IN THE TREATMENT AND PREVENTION OF INFECTIONS

5

[0001] This application claims benefit of U.S. Provisional Patent Application Serial No. 61/654,519, filed June 1, 2012, which is hereby incorporated by reference in its entirety.

10

**FIELD OF THE INVENTION**

[0002] The present invention relates to normalizing ceramide levels to prevent and/or treat pathogenic infections in a subject with cystic fibrosis, Chronic Obstructive Lung Disease (COPD), and/or an open wound.

15

**BACKGROUND OF THE INVENTION**

[0003] Cystic Fibrosis (“CF”) is the most common autosomal recessive disorder in Europe and the USA, impacting one in every 2500 children born in Western Countries. It is a disease caused by mutations of the CF transmembrane conductance regulator protein (“CFTR”). While this genetic mutation leads to several respiratory, reproductive and gastrointestinal complications, the primary cause of morbidity and mortality in these subjects results from the destructive effects of chronic pulmonary colonization with *Pseudomonas aeruginosa* (“*P. aeruginosa*”). Medical records indicate approximately 80% of subjects with CF will host *P. aeruginosa* by the age of 25. See Cystic Fibrosis Foundation Subject Registry: Annual Data Report (2010). In addition to the increased susceptibility to *P. aeruginosa*, CF lungs are characterized by chronic inflammation and progressive fibrosis. At present, the molecular mechanisms that mediate the hallmarks of CF disease, *i.e.*, infection susceptibility, inflammation, and fibrosis, require definition.

20  
25

[0004] *P. aeruginosa* infection of epithelial cells is initiated by contact of the pathogen with the cell surface. Several binding molecules for *P. aeruginosa* have been identified, including CFTR, Fibronectin,  $\alpha 5\beta 1$ -integrin and glycolipids including asialo-GM1. See Pier *et. al.*, "Role Of Mutant CFTR In  
5 Hypersusceptibility Of Cystic Fibrosis Subjects To Lung Infections," *Science*. 271, 64-67 (1996); Schroeder *et. al.*, "CFTR Is A Pattern Recognition Molecule That Extracts *Pseudomonas aeruginosa* LPS From The Outer Membrane Into Epithelial Cells And Activates NF-kappa B Translocation," *Proc. Natl. Acad. Sci. U.S.A.* 99, pp. 6907-6912 (2002); deBentzmann *et. al.*, "Asialo GM1 Is A  
10 Receptor For *Pseudomonas aeruginosa* Adherence To Regenerating Respiratory Epithelial Cells," *Infect. Immun.* 64(5) pp.1582-1588 (1996); deBentzmann *et. al.*, "Pseudomonas aeruginosa Adherence To Remodeling Respiratory Epithelium," *Eur. Respir. J.* 9 pp. 2145- 2150 (1996); Roger *et. al.*, "Fibronectin And  $\alpha 5\beta 1$ -integrin Mediate Binding Of *Pseudomonas aeruginosa* To Repairing Airway  
15 Epithelium," *Eur. Respir. J.* 13 pp. 1301-1309 (1999); Saiman *et. al.*, "Pseudomonas aeruginosa Pili Bind To AsialoGM1 Which Is Increased On The Surface Of Cystic Fibrosis Epithelial Cells," *J. Clin. Invest.* 92 pp. 1875-1880 (1993); and Davies *et. al.*, "Reduction In The Adherence Of *Pseudomonas aeruginosa* To Native Cystic Fibrosis Epithelium With Anti-AsialoGM1 Antibody  
20 And Neuraminidase Inhibition," *Eur. Respir. J.*; 13 pp. 565-570 (1999).

[0005] Therefore, identification of epithelial receptors for *P. aeruginosa* that are specifically altered in CF and involved in the high infection susceptibility of these subjects to *P. aeruginosa*, is an important consideration in the development of new strategies for CF—and concomitant pathogenic infection—  
25 prophylaxis and treatment. Such molecules would be ideal targets to prevent the initial contact of the pathogen with bronchial epithelial cells in CF subjects and, thus, to prevent the infection very early.

[0006] Current methods of treating and preventing disease pathogenesis in subjects afflicted with a disease or condition raise toxicity and efficacy concerns.

30 [0007] The present invention is directed to overcoming these deficiencies in the art by, for example, by correcting the abnormal expression of primary

binding molecules of bacterial pathogens to bronchial epithelial cells *in vivo* through a unique membrane lipid mediated mechanism.

### SUMMARY OF THE INVENTION

5 [0008] One aspect of the present invention is directed to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, Chronic Obstructive Lung Disease (COPD), and/or an open wound. This method involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective  
10 to reduce ceramide and to treat or prevent the pathogenic infection in the selected subject.

[0009] Another aspect of the present invention relates to administering to the subject a ceramidase in combination with other agents to reduce ceramide or reduce infections. Such agents may include but not be limited to antibiotics,  
15 reagents to reduce mucus viscosity, chaperone agents to enhance the function of the Cystic Fibrosis transmembrane protein (CFTR), or acid sphingomyeliase inhibitors.

[0010] Another aspect of the present invention relates to selecting said subject based on the level of ceramide in their cells, tissues or fluids, and/or the  
20 level of an endogenous ceramidase enzyme.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0011] Figures 1A and 1B show paraffin embedded sections of mouse lungs. Figure 1A is a representative section of wild type mice, CerS2-deficient mice, and Cystic Fibrosis mice lung stained with Cy3-anti-ceramide antibodies  
25 and then analyzed by confocal microscopy. Figure 1B is a representative section of wild type mice, CerS2-deficient mice, and Cystic Fibrosis mice lung stained

with the same antibody 2 hours after the mouse received a single inhalation of acid ceramidase (“AC”). Results are representative of at least 6 mice per group.

[0012] Figure 2 demonstrates that recombinant acid ceramidase prevents *P. aeruginosa* infection in the lungs of mice accumulating ceramide. Two mouse models were used. One (CerS2<sup>-/-</sup>) is a genetic knockout for a ceramide producing enzyme, ceramide synthase 2. Another (Cftr<sup>-/-</sup>) has a mutation in the Cystic Fibrosis transmembrane protein gene and are a model of Cystic Fibrosis. The wild type, CerS2<sup>-/-</sup> or Cftr<sup>-/-</sup> mice either received a single inhalation of saline (light grey) or acid ceramidase (dark grey), and then were infected with *P. aeruginosa*. Two hours later they were sacrificed and the titer of *P. aeruginosa* remaining in the mouse lungs was determined.

[0013] Figure 3 shows results of mice that inhaled 100 µg AC in 0.8 mL of 0.9% NaCl 30 to 45 minutes before intranasal infection with  $1 \times 10^8$  colony-forming units (CFU) of *P. aeruginosa* strain 762 or ATCC 27853. The lungs were removed 4 hours after infection, homogenized, lysed in 5 mg/mL saponin for 10 minutes, and washed. Aliquots were plated on LB plates and allowed to grow overnight. CFUs on the LB plates were counted to determine the number of *P. aeruginosa* bacteria in the lung. Shown are means  $\pm$  s.d. of four independent experiments.

20

## DETAILED DESCRIPTION OF THE INVENTION

[0014] In practicing the present invention, many conventional techniques in molecular biology, protein biochemistry, cell biology, immunology, microbiology and recombinant DNA are used. These techniques are well-known and are explained in, *e.g.*, *Current Protocols in Molecular Biology*, Vols. I-III, Ausubel, Ed. (1997); Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, Second Ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)); *DNA Cloning: A Practical Approach*, Vols. I and II, Glover, Ed. (1985); *Oligonucleotide Synthesis*, Gait, Ed. (1984); *Nucleic Acid Hybridization*, Hames & Higgins, Eds. (1985); *Transcription and Translation*, Hames & Higgins,

Eds. (1984); *Animal Cell Culture*, Freshney, Ed. (1986); *Immobilized Cells and Enzymes* (IRL Press, 1986); Perbal, *A Practical Guide to Molecular Cloning*; the series, *Meth. Enzymol.*, (Academic Press, Inc., 1984); *Gene Transfer Vectors for Mammalian Cells*, Miller & Calos, Eds. (Cold Spring Harbor Laboratory, New York (1987)); and *Meth. Enzymol.*, Vols. 154 and 155, Wu & Grossman, and Wu, Eds., respectively, all of which are hereby incorporated by reference in their entirety. Methods to detect and measure levels of polypeptide gene expression products, *i.e.*, gene translation level, are well-known in the art and include the use of polypeptide detection methods such as antibody detection and quantification techniques. *See also*, Strachan & Read, *Human Molecular Genetics*, Second Edition. (John Wiley and Sons, Inc., New York (1999), which is hereby incorporated by reference in its entirety.

**[0015]** It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present invention are described below in various levels of detail in order to provide a substantial understanding of the present technology. The definitions of certain terms as used in this specification are provided below. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

**[0016]** Underlying disease conditions can predispose a subject to acute and/or chronic pathogenic infections. As used herein a “disease condition” refers to a pathological disease or condition of any kind or origin, which a subject harbors. Accordingly, disease conditions include the subject matter identified by the following diseases and/or terms including, but not limited to, *e.g.*, a respiratory disease, lung disease, Cystic Fibrosis (“CF”), chronic obstructive pulmonary disease (“COPD”), emphysema, asthma, pulmonary fibrosis, chronic bronchitis, pneumonia, pulmonary hypertension, lung cancer, sarcoidosis, necrotizing pneumonia, asbestosis, aspergilloma, aspergillosis, acute invasive atelectasis, eosinophilic pneumonia, pleural effusion, pneumoconiosis, pneumocystosis, pneumothorax, pulmonary actinomycosis, pulmonary alveolar proteinosis, pulmonary anthracis, pulmonary arteriovenous malformation, pulmonary edema, pulmonary embolus, pulmonary histiocytosis X (eosinophilic granuloma),

pulmonary nocardiosis, pulmonary tuberculosis, pulmonary veno-occlusive disease, rheumatoid lung disease, and/or an open wound. Such diseases typically manifest an increased susceptibility of a subject for pathogenic infection, *i.e.*, compared to subjects not afflicted with a disease condition.

- 5 [0017] For example, subjects suffering from CF, COPD, and/or an open wound, may possess a high susceptibility for acquiring acute and/or chronic pathogenic infections, such as, *e.g.*, bacterial, viral, fungal, protozoan, and/or prionic pathogenic infections. Bacterial pathogens include, without limitation, *Bacillus anthracis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Campylobacter*
- 10 *jejuni*, *Chlamydia trachomatis*, *Clostridium botulinum*, *Clostridium tetani*, *Corynebacterium diphtheriae*, *Escherichia coli*, enterohemorrhagic *E. coli*, enterotoxigenic *E. coli*, *Haemophilus influenzae* type B and non-typable, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Mycobacterium spp.*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*,
- 15 *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pneumococcus spp.*, *Pseudomonas aeruginosa*, *Rickettsia*, *Salmonella spp.*, *Shigella spp.*, *Staphylococcus spp.*, *Staphylococcus aureus*, *Streptococcus spp.*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Streptococcus B*, Group A beta hemolytic *Streptococcus*, *Streptococcus mutans*, *Treponema pallidum*, *Vibrio cholerae*, and *Yersinia pestis*.
- 20 In some embodiments, the pathogenic infection is a *Pseudomonas* infection. In some embodiments, the *Pseudomonas* infection is a *Pseudomonas aeruginosa* infection.

- [0018] Viral pathogens include, without limitation, RNA viruses, DNA viruses, adenoviridae (*e.g.*, mastadenovirus and aviadenovirus), herpesviridae
- 25 (*e.g.*, herpes simplex virus 1, herpes simplex virus 2, herpes simplex virus 5, and herpes simplex virus 6), leviviridae (*e.g.*, levivirus, *enterobacteria* phage MS2, allovirus), poxyviridae (*e.g.*, chordopoxyvirinae, parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus, suipoxvirus, molluscipox virus, and entomopoxyvirinae), papovaviridae (*e.g.*, polyomavirus and papillomavirus),
- 30 paramyxoviridae (*e.g.*, paramyxovirus, parainfluenza virus 1, morbillivirus such as measles virus, rubulavirus (such as mumps virus), pneumonoviridae (*e.g.*, pneumovirus, human respiratory syncytial virus), metapneumovirus (*e.g.*, avian

pneumovirus and human metapneumo virus), picornaviridae (e.g., enterovirus, rhinovirus, hepatovirus such as human hepatitis A virus, cardiovirus, and aphthovirus), reoviridae (e.g., orthoreo virus, orbivirus, rotavirus, cyto virus, fujivirus, phytoreo virus, and oryzavirus), retroviridae (e.g., mammalian type B  
5 retroviruses, mammalian type C retroviruses, avian type C retroviruses, type D retrovirus group, BLV-HTLV retroviruses, lentivirus (such as human immunodeficiency virus 1 and human immunodeficiency virus 2; and spuma virus), flaviviridae (e.g., hepatitis C virus), hepadnaviridae (e.g., hepatitis B virus), togaviridae (e.g., alphavirus - such as sindbis virus and rubivirus, such as  
10 rubella virus), rhabdoviridae (e.g., vesiculovirus, lyssavirus, ephemera virus, cytorhabdovirus, and nucleorhabdovirus), arenaviridae (e.g., arenavirus, lymphocytic choriomeningitis virus, Ippy virus, and lassa virus), and coronaviridae (e.g., coronavirus and torovirus), Cytomegalovirus (mononucleosis), Dengue virus (dengue fever, shock syndrome), Epstein-Barr  
15 virus (mononucleosis, Burkitt's lymphoma), Human T-cell lymphotropic virus type 1 (T-cell leukemia), Influenza A, B, and C (respiratory disease), Japanese encephalitis virus (pneumonia, encephalopathy), Poliovirus (paralysis), Rhinovirus (common cold), Rubella virus (fetal malformations), Vaccinia virus (generalized infection), Yellow fever virus (jaundice, renal and hepatic failure),  
20 and Varicella zoster virus (chickenpox).

[0019] Pathogenic fungi include, without limitation, the genera *Aspergillus* (e.g., *Aspergillus fumigates*), *Blastomyces*, *Candida* (e.g., *Candida albicans*), *Coccidioides*, *Cryptococcus*, *Histoplasma*, *Phycomyces*, *Tinea corporis*, *Tinea unguis*, *Sporothrix schenckii*, and *Pneumocystis carinii*. Pathogenic  
25 protozoan include, without limitation, *Trypanosome spp.*, *Leishmania spp.*, *Plasmodium spp.*, *Entamoeba spp.*, and *Giardia spp.* such as *Giardia lamblia*

[0020] Because the molecular mechanisms which precipitate increased susceptibility to a pathogenic infection in subjects afflicted with a disease condition are not well understood, elucidating the pathology of, for example, *P. aeruginosa*, with respect to cellular attachment and internalization, are important  
30 considerations for preventing and treating subjects prone to acquiring such infections.

[0021] Integrins are receptor molecules which function to coordinate cellular processes relating to, *e.g.*, attachment and adhesion. Integrins, however, are not characteristically expressed at the luminal surface of normal, healthy bronchial epithelial cells, and epithelial cell-layer tight junctions prevent the contact of bronchial pathogens with the basolateral pole of epithelial cells—where integrins typically reside.

[0022] The term “elevated levels” or “higher levels” as used herein refers to levels of a measurable marker, molecule, or protein, such as, for example, ceramide, that are higher than what would normally be observed in a comparable sample from control or normal subjects, *i.e.*, a reference value or control levels or normalized levels. In some embodiments, “control levels”, *i.e.*, normal levels, refer to a range of that would normally be expected to be observed in a sample from a subject that does not have a disease condition. A control level may be used as a “reference level” for comparative purposes, as further detailed, *infra*.

15 “Elevated levels” therefore refer to levels that are above the range of control levels. The ranges accepted as “elevated levels” or “control levels” are dependent on a number of factors. The skilled artisan is capable of considering the relevant factors and establishing appropriate reference ranges for “control values” and “elevated values” of the present invention. For example, a series of samples from control subjects and subjects diagnosed with CF can be used to establish ranges that are “normal” or “control” levels and ranges that are “elevated” or “higher” compared to the control range or level.

[0023] Ceramidases are enzymes capable of hydrolyzing ceramide into fatty acids and a sphingoid base (sphingosine), which is involved in cellular proliferation and intracellular signal transduction. The ceramidase, after enzymatic activation, facilitates ceramide hydrolysis into individual fatty acid and sphingosine components. *See* Gatt, “Enzymic Hydrolysis and Synthesis of Ceramide,” *J. Biol. Chem.* 238:3131–3 (1963); Gatt, “Enzymatic Hydrolysis of Sphingolipids. 1. Hydrolysis and Synthesis of Ceramides by an Enzyme from Rat Brain,” *J. Biol. Chem.* 241:3724–31 (1966); Hassler & Bell, “Ceramidase: Enzymology and Metabolic Roles,” *Adv. Lip. Res.* 26:49–57 (1993), all of which are hereby incorporated by reference in their entirety. There is no *de novo*

pathway for cells to generate sphingosine, and it is therefore only generated by ceramide hydrolysis pursuant to the enzymatic action of a ceramidase.

**[0024]** One aspect of the present invention is directed to a method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound. This method of the present invention involves selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and administering to the selected subject a ceramidase under conditions effective to reduce ceramide and to treat or prevent the pathogenic infection in the selected subject.

**[0025]** As described herein, an “open wound” refers to a type of injury in which an epithelial layer, *i.e.*, skin, is torn, cut, and/or punctured. In some embodiments, an open wound refers to a sharp injury which damages the dermis of the skin and concomitantly increases the chance of acquiring an infection. The term “open wound” also encompasses burns.

**[0026]** The methods of the present invention further involve selecting the subject based on elevated ceramide levels compared to a reference level for a subject not having Cystic Fibrosis, COPD, and/or an open wound. As used herein, the term “reference level” refers to a level of a substance, *e.g.*, ceramide, which may be of interest for comparative purposes. In some embodiments, a reference level may be the level or concentration of a protein expressed as an average of the level or concentration from samples of a control population of healthy (disease-free and/or pathogen-free) subjects. In other embodiments, the reference level may be the level in the same subject at a different time, *e.g.*, before the present invention is employed, such as the level determined prior to the subject developing a disease, disease condition, and/or pathogenic infection, prior to initiating therapy, such as, for example, ceramidase therapy, or earlier in the therapy.

**[0027]** Exemplary methods of comparing ceramide levels between a subject and a reference level include, but are not limited to, comparing differences in detected ceramide levels, based on results of one or more protein assays as

further described, *infra*. In some embodiments, ceramide levels are higher in the presence of a disease condition as described herein. A subject with, or a sample possessing, a lower detected ceramide level compared to a reference level would indicate that the subject may not require ceramidase therapy and/or the subject  
5 may not have a disease condition as described herein.

**[0028]** The method of the present invention further relates to selecting a subject based on ceramide level in lung epithelium, nasal epithelium, mucus, and/or cells isolated from an open wound site. In some embodiments, administering is carried out under conditions effective to normalize ceramide  
10 levels in the subjects' respiratory epithelia, mucus, or cells at an open wound site. In some embodiments, the ceramidase is an acid ceramidase ("AC"), such as, but not limited to, the AC's listed in Table 1 below.

**[0029]** Acid ceramidase (*N*-acylsphingosine deacylase, I.U.B.M.B. Enzyme No. EC 3.5.1.23) is one particular ceramidase responsible for the  
15 catabolism of ceramide. Due to its involvement in the human genetic disorder Farber Lipogranulomatosis, AC is one of the most extensively studied members of the ceramidase enzyme family. The protein has been purified from several sources, and the human and mouse cDNAs and genes have been obtained. *See* Bernardo *et al.*, "Purification, Characterization, and Biosynthesis of Human Acid  
20 Ceramidase," *J. Biol. Chem.* 270:11098–102 (1995); Koch *et al.*, "Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase. Identification of the First Molecular Lesion Causing Farber Disease," *J. Biol. Chem.* 271:33110–5 (1996); Li *et al.*, "Cloning and Characterization of the Full-length cDNA and Genomic Sequences Encoding  
25 Murine Acid Ceramidase," *Genomics* 50:267–74 (1998); Li *et al.*, "The Human Acid Ceramidase Gene (ASAH): Chromosomal Location, Mutation Analysis, and Expression," *Genomics* 62:223–31 (1999), all of which are hereby incorporated by reference in their entirety.

**[0030]** As described above, AC is a ceramidase which catalyzes the  
30 hydrolysis of ceramide to sphingosine and free fatty acid. *See* Bernardo *et al.*, "Purification, Characterization, and Biosynthesis of Human Acid Ceramidase," *J.*

*Biol. Chem.* 270(19):11098–102 (1995), which is hereby incorporated by reference in its entirety. Mature AC is a ~50kDa protein composed of an  $\alpha$ -subunit (~13kDa) and a  $\beta$ -subunit (~40kDa). *See* Bernardo *et al.*, “Purification, Characterization, and Biosynthesis of Human Acid Ceramidase,” *J. Biol. Chem.* 270(19):11098–102 (1995), which is hereby incorporated by reference in its entirety. It is produced through cleavage of the AC precursor protein (*see* Ferlinz *et al.*, “Human Acid Ceramidase: Processing, Glycosylation, and Lysosomal Targeting,” *J. Biol. Chem.* 276(38):35352–60 (2001), which is hereby incorporated by reference in its entirety), which is the product of the *Asah1* gene (NCBI UniGene GeneID No. 427, which is hereby incorporated by reference in its entirety).

[0031] AC function and/or activity, moreover, is directly related to surrounding pH. In fact, it is normally found within lysosomes with an acidic pH of ~4.5, and in the absence of AC activity in patients with Farber Lipogranulomatosis ceramides accumulate in lysosomes.

[0032] In addition, recent studies have shown that an increase in intracellular compartment pH reduces AC activity/function by up to 90%. *See* Teichgräber *et al.*, “Ceramide Accumulation Mediate Inflammation, Cell Death And Infection Susceptibility In Cystic Fibrosis,” *Nat Med.* 14(4), pp. 382-391 (2008), which is hereby incorporated by reference in its entirety. In some respects, these results mimic Farber’s disease, which is caused by a deficiency of AC and results in an accumulation of ceramide. *See* He *et al.*, “Purification And Characterization Of Recombinant, Human Acid Ceramidase,” *J. Biol. Chem.* 278, 32978–32986 (2003), which is hereby incorporated by reference in its entirety. Furthermore, at a pH of 5.9, AC has been shown to possess a reverse activity—producing ceramide instead of consuming it. *See id.* This activity in concert with impaired Asm function—at increasing vesicular pH levels—can result in a net accumulation of ceramide. *See* Teichgräber *et al.*, “Ceramide Accumulation Mediate Inflammation, Cell Death And Infection Susceptibility In Cystic Fibrosis,” *Nat Med.* 14(4), pp. 382-391 (2008), which is hereby incorporated by reference in its entirety.

[0033] Other studies have shown that CFTR deficiency in alveolar macrophages result in a lysosomal pH shift from pH 4.5 to at least pH 5.9. *See Di et al. "CFTR Regulates Phagosome Acidification In Macrophages And Alters Bactericidal Activity," Nat. Cell Biol. 8, 933–944 (2006),* which is hereby incorporated by reference in its entirety. As such, the present invention surprisingly functions to prevent and/or treat pathogenic infections in CF subjects at least because AC would not be expected to decrease elevated ceramide levels in CF subjects possessing increased lysosomal pH. Moreover, AC would not be expected to function on the accumulating ceramide in the lung epithelial cell membrane.

[0034] The AC's that can be used in the context of the present invention include, without limitation, those set forth in Table 1 below. In all aspects of the present invention, the AC can be homologous (*i.e.*, derived from the same species) or heterologous (*i.e.*, derived from a different species) to the tissue, cells, and/or subject being treated.

**Table 1. Exemplary Acid Ceramidase Family Members**

<i>Homo sapiens</i>		<i>Caenorhabditis elegans</i>	
UniProt	Q13510, Q9H715, Q96AS2	UniProt	O45686
OMIM	228000	IntAct	O45686
NCBI Gene	427	NCBI Gene	173120
NCBI RefSeq	NP_808592, NP_004306	NCBI RefSeq	NP_493173
NCBI RefSeq	NM_177924, NM_004315	NCBI RefSeq	NM_060772
NCBI UniGene	427	NCBI UniGene	173120
NCBI Accession	Q13510, AAC73009	NCBI Accession	O45686, CAB05556
<i>Mus musculus</i>		<i>Danio rerio</i>	
UniProt	Q9WV54, Q3U8A7, Q78P93	UniProt	Q5XJR7
NCBI Gene	11886	NCBI Gene	450068
NCBI RefSeq	NP_062708	NCBI RefSeq	NP_001006088
NCBI RefSeq	NM_019734	NCBI RefSeq	NM_001006088
NCBI UniGene	11886	NCBI UniGene	450068
NCBI Accession	AK151208, AK034204	NCBI Accession	AAH83231, CB360968
<i>Gallus gallus</i>		<i>Rattus norvegicus</i>	
UniProt	Q5ZK58	UniProt	Q6P7S1, Q9EQJ6
NCBI Gene	422727	NCBI Gene	84431
NCBI RefSeq	NP_001006453	NCBI RefSeq	NP_445859
NCBI RefSeq	NM_001006453	NCBI RefSeq	NM_053407
NCBI UniGene	422727	NCBI UniGene	84431
NCBI Accession	CAG31885, AJ720226	NCBI Accession	AAH61540, AF214647
<i>Pan troglodytes</i>			
NCBI Gene	464022		
NCBI RefSeq	XP_519629		
NCBI RefSeq	XM_519629		
NCBI UniGene	464022		

[0035] In some embodiments, determining the level of ceramide and/or AC concentration and/or activity is carried out prior to treatment. Assays suitable for determining ceramide concentrations and/or ceramidase levels or activity are readily apparent to the skilled artisan. Suitable methods include, for example, activity assays (*see* Eliyahu *et al.*, “Acid Ceramidase is a Novel Factor Required for Early Embryo Survival,” *FASEB J.* 21(7):1403–9 (2007), which is hereby incorporated by reference in its entirety, and well known techniques, such as, western blotting to determine the relative amount of ceramidase protein and/or activity present in the sample (where a higher amount of ceramidase protein correlates to a higher ceramidase activity level). *See* Eliyahu *et al.*, “Acid Ceramidase is a Novel Factor Required for Early Embryo Survival,” *FASEB J.* 21(7):1403–9 (2007), which is hereby incorporated by reference in its entirety.

[0036] As used herein, the term “assay” refers to an assay for detecting the presence or absence of ceramide and/or ceramidase, in a given sample of a bodily fluid. Also included are quantitative assays, which measure the amount of a substance in a sample. As used herein, the term “sample” is used in its broadest sense. In one sense, it is meant to include a specimen or culture obtained from biological samples. The bodily fluid sample is selected from the group consisting of serum, synovial fluid, cerebrospinal fluid, and peritoneal fluid. Of particular interest are samples that are serum. Those skilled in the art will recognize that plasma or whole blood or a sub-fraction of whole blood may also be used. Biological fluid samples may be obtained from animals (including humans) and include blood products, such as plasma, serum and the like. In some embodiments, the sample contains a level of ceramide or ceramidase, which can be readily ascertained by the methods described herein and those well known in the art.

[0037] Immunoassays, in their most simple and direct sense, are binding assays involving binding between antibodies and antigen. Many types and formats of immunoassays are known and all are suitable for detecting, *e.g.*, ceramide levels. Examples of immunoassays are enzyme linked immunosorbent assays (“ELISAs”), enzyme linked immunospot assay (“ELISPOT”), radioimmunoassays (“RIA”) (*see* Ferlinz *et al.*, “Human Acid Ceramidase:

Processing, Glycosylation, and Lysosomal Targeting,” *J. Biol. Chem.* 276(38):35352–60 (2001), which is hereby incorporated by reference in its entirety, radioimmune precipitation assays (“RIPA”), immunobead capture assays, dot blotting, gel-shift assays, flow cytometry, immunohistochemistry, 5 fluorescence microscopy, protein arrays, multiplexed bead arrays, magnetic capture, *in vivo* imaging, fluorescence resonance energy transfer (“FRET”), and fluorescence recovery/localization after photobleaching (“FRAP/FLAP”). The steps of various useful immunodetection methods have been described in the scientific literature, such as, *e.g.*, Maggio *et al.*, *Enzyme-Immunoassay* (1987) and 10 Nakamura, *et al.*, “Enzyme Immunoassays: Heterogeneous and Homogeneous Systems, Handbook of Experimental Immunology,” Vol. 1: *Immunochemistry*, 27.1-27.20 (1986), each of which is incorporated herein by reference in its entirety.

**[0038]** In general, immunoassays involve contacting a sample suspected of 15 containing a molecule or protein of interest (such as, ceramide and/or ceramidase) with an antibody to the molecule or protein of interest, under conditions effective to allow the formation of immunocomplexes. In this regard, the skilled artisan will be able to assess the presence and or level of specific molecules or proteins of interest in a given sample.

20 **[0039]** Immunoassays can include methods for detecting or quantifying the amount of a molecule or protein of interest in a sample, which methods generally involve the detection or quantitation of any immune complexes formed during the binding process. In general, the detection of immunocomplex formation is well known in the art and can be achieved through the application of 25 numerous approaches. These methods are generally based upon the detection of a label or marker, such as any radioactive, fluorescent, biological or enzymatic tags or any other known label. *See, for example*, U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149 and 4,366,241, each of which is incorporated herein by reference in its entirety.

30 **[0040]** One particularly effective non-specific assay used to detect total proteins is the Bradford protein assay. *See* Bradford, M. M., “A Rapid and

Sensitive Method for the Quantitation of Microgram Quantities of Proteins Utilizing the Principle of Protein-Dye Binding,” *Anal. Biochem.* 72:248–254 (1976), which is hereby incorporated by reference in its entirety.

[0041] The Bradford protein assay uses a dye stock of Coomassie Blue G (C.I.# 42655) (100 mg), which is dissolved in 50 mL of methanol. The solution is added to 100 mL of 85% H<sub>3</sub>PO<sub>4</sub>, and diluted to 200 mL with water, resulting in a dark red. The final reagent concentrations of the assay are 0.5 mg/mL Coomassie Blue G, 25% methanol, and 42.5% H<sub>3</sub>PO<sub>4</sub>. The assay reagent of the Bradford assay is prepared by diluting 1 part dye stock with 4 parts distilled H<sub>2</sub>O. The resulting color should be brown with a pH of 1.1. A series of protein standards are prepared in the same buffer as the samples to be assayed, using bovine serum albumin (“BSA”) with concentrations of 0, 250, 500, 750, and 1500 µg/mL for a standard assay. The absorbance is read at 595 nm for standard assay procedure and 450 nm for a micro assay (Dynex Technologies, Chantilly, VA), and the ratio of the absorbances, 595 nm over 450 nm, was used for standard curve calculations. *See Zor, et al.*, “Linearization of the Bradford Protein Assay Increases Its Sensitivity: Theoretical and Experimental Studies,” *Anal. Biochem.* 236:302–308 (1996), which is hereby incorporated by reference in its entirety.

[0042] In some embodiments, the methods of the present invention are carried out by administering an AC precursor protein, which is then converted into an active acid ceramidase protein by the cell. In particular, the AC precursor protein undergoes autoproteolytic cleavage into the active form (composed of  $\alpha$ - and  $\beta$ -subunits). This is promoted by the intracellular environment, and based on highly conserved sequences at the cleavage site of AC precursor proteins across species, is expected to occur in most, if not all, cell types. Suitable acid ceramidase precursor proteins include those set forth in Table 1, *supra*. As will be apparent to the skilled artisan, the precursor protein could optionally be contained in a culture medium to which the cell is exposed. Embodiments in which the precursor protein is taken up by the host subject or cell of interest and converted into active acid ceramidase is thus contemplated.

[0043] Yet another approach for administering proteins or polypeptide agents of the present invention, *e.g.*, AC, involves preparation of chimeric proteins according to U.S. Patent No. 5,817,789 to Heartlein *et al.*, which is hereby incorporated by reference in its entirety. The chimeric protein can include a  
5 ligand domain and the polypeptide agent (*e.g.*, AC, AC precursor protein). The ligand domain is specific for receptors located on a target cell. Thus, when the chimeric protein is delivered to the subject, cell, and/or culture medium, the chimeric protein will be internalized.

[0044] Depending on the level or activity of a substance, *e.g.*, ceramide and/or ceramidase, one or more additional agents may be administered in  
10 combination with the ceramidase, *e.g.*, AC, in accordance with the methods of the present invention. In some embodiments, the one or more additional agents are selected from the group consisting of one or more additional ceramide reducing agents, one or more acid sphingomyelinase inhibitors, one or more agents to  
15 reduce infection, and combinations thereof. Suitable agents to reduce infection include antibiotics (*e.g.*, inhaled Tobramycin, TOBI), reagents that block binding of pathogens to lung epithelium, reagents to reduce mucus viscosity (*e.g.*, Dornase alfa, Pulmozyme), chaperone reagents to enhance missing protein function (*e.g.*, Ivacaftor, Kalydeco), and combinations thereof. In some embodiments, the  
20 ceramidase, *e.g.*, AC, is administered simultaneously, separately, or sequentially with the one or more additional agents.

[0045] As used herein, the term “simultaneous” therapeutic use refers to the administration of at least two active ingredients by the same route and at the same time or at substantially the same time. As used herein, the term “separate”  
25 therapeutic use refers to an administration of at least two active ingredients at the same time or at substantially the same time by different routes. As used herein, the term “sequential” therapeutic use refers to administration of at least two active ingredients at different times, the administration route being identical or different. More particularly, sequential use refers to the whole administration of one of the  
30 active ingredients before administration of the other or others commences. It is thus possible to administer one of the active ingredients over several minutes,

hours, or days before administering the other active ingredient or ingredients.  
There is no simultaneous treatment in this case.

[0046] Administration can be accomplished either *via* systemic administration to the subject or *via* targeted administration to affected tissues, organs, and/or cells. The therapeutic agent (*i.e.*, AC, AC precursor protein, 5 nucleic acid encoding AC / AC precursor protein) may be administered to a non-targeted area along with one or more agents that facilitate migration of the therapeutic agent to (and/or uptake by) a targeted tissue, organ, or cell. Additionally and/or alternatively, the therapeutic agent itself can be modified to 10 facilitate its transport to (and uptake by) the desired tissue, organ, or cell, as will be apparent to one of ordinary skill in the art.

[0047] Any suitable approach for delivery of the agents can be utilized to practice this aspect of the present invention. Typically, the therapeutic agent will be administered to a patient in a vehicle that delivers the therapeutic agent(s) to 15 the target cell, tissue, or organ. Exemplary routes of administration include, without limitation, by intratracheal inoculation, aspiration, airway instillation, aerosolization, nebulization, intranasal instillation, oral or nasogastric instillation, intraperitoneal injection, intravascular injection, topically, transdermally, parenterally, subcutaneously, intravenous injection, intra-arterial injection (such as 20 *via* the pulmonary artery), intramuscular injection, intrapleural instillation, intraventricularly, intralesionally, by application to mucous membranes (such as that of the nose, throat, bronchial tubes, genitals, and/or anus), or implantation of a sustained release vehicle.

[0048] In some embodiments, a ceramidase, *e.g.*, AC, is administered 25 orally, topically, intranasally, intraperitoneally, intravenously, subcutaneously, or by aerosol inhalation. In some embodiments, a ceramidase, *e.g.*, AC, is administered *via* aerosol inhalation. In some embodiments, the ceramidase and/or additional agents can be incorporated into pharmaceutical compositions suitable for administration, as described herein.

[0049] The agents of the present invention, *e.g.*, AC, may be orally administered, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1% of the agent. The percentage of the agent in these compositions may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of the agent in such therapeutically useful compositions is such that a suitable dosage will be obtained.

[0050] The tablets, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, or alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a fatty oil.

[0051] The agents, *e.g.*, AC, may also be administered parenterally. Solutions or suspensions of the agent can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

[0052] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form

must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for  
5 example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0053] The agents, *e.g.*, AC, according to the present invention may also be administered directly to the airways in the form of an aerosol. For use as aerosols, the compounds of the present invention in solution or suspension may be  
10 packaged in a pressurized aerosol container together with suitable propellants, for example, hydrocarbon propellants like propane, butane, or isobutane with conventional adjuvants. The materials of the present invention also may be administered in a non-pressurized form.

[0054] Exemplary delivery devices include, without limitation, nebulizers,  
15 atomizers, liposomes (including both active and passive drug delivery techniques) (Wang & Huang, "pH-Sensitive Immunoliposomes Mediate Target-cell-specific Delivery and Controlled Expression of a Foreign Gene in Mouse," *Proc. Nat'l Acad. Sci. USA* 84:7851-5 (1987); Bangham *et al.*, "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," *J. Mol. Biol.* 13:238-52 (1965);  
20 U.S. Patent No. 5,653,996 to Hsu; U.S. Patent No. 5,643,599 to Lee *et al.*; U.S. Patent No. 5,885,613 to Holland *et al.*; U.S. Patent No. 5,631,237 to Dzau & Kaneda; and U.S. Patent No. 5,059,421 to Loughrey *et al.*; Wolff *et al.*, "The Use of Monoclonal Anti-Thy1 IgG1 for the Targeting of Liposomes to AKR-A Cells *in Vitro* and *in Vivo*," *Biochim. Biophys. Acta* 802:259-73 (1984), each of which  
25 is hereby incorporated by reference in its entirety), transdermal patches, implants, implantable or injectable protein depot compositions, and syringes. Other delivery systems which are known to those of skill in the art can also be employed to achieve the desired delivery of the therapeutic agent to the desired organ, tissue, or cells.

30 [0055] Administration can be carried out as frequently as required and for a duration that is suitable to provide effective prophylaxis or efficacy against a

pathogen. For example, administration can be carried out with a single sustained-release dosage formulation or with multiple daily doses.

[0056] The amount to be administered will, of course, vary depending upon the treatment regimen. Generally, an agent is administered to achieve an amount effective for improving pathogenic clearance. Thus, a therapeutically effective amount can be an amount which is capable of at least partially preventing and/or treating a pathogenic infection. This includes, without limitation, delaying the onset of infection. The dose required to obtain an effective amount may vary depending on the agent, formulation, and individual to whom the agent is administered.

[0057] Dosage, toxicity and therapeutic efficacy of the agents or compositions of the present invention can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds which exhibit high therapeutic indices may be desirable. While compositions that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compositions to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0058] As such, the ceramidase is administered in a therapeutically effective amount, in some embodiments. As used herein, the terms “therapeutically effective amount”, “effective amount”, or “pharmaceutically effective amount” of an agent, protein, compound, and/or composition, is a quantity sufficient to achieve a desired therapeutic and/or prophylactic effect, *e.g.*, an amount which results in the prevention of, or a decrease in, the symptoms associated with a disease that is being treated.

[0059] The effective amount of an agent or composition of the present invention administered to the subject will depend on the type and severity of the

disease and on the characteristics of the individual, such as general health, age, sex, body weight and tolerance to drugs. It will also depend on the degree, severity and type of disease. The skilled artisan will be able to determine appropriate dosages depending on these and other factors. The compositions of  
5 the present invention can also be administered in combination with one or more additional therapeutic compounds.

[0060] Typically, the therapeutic agent will be administered as a pharmaceutical formulation that includes the therapeutic agent and any pharmaceutically acceptable adjuvants, carriers, excipients, and/or stabilizers, and  
10 can be in solid or liquid form, such as tablets, capsules, powders, solutions, suspensions, or emulsions. The compositions preferably contain from about 0.01 to about 99 weight percent, more preferably from about 2 to about 60 weight percent, of therapeutic agent together with the adjuvants, carriers and/or excipients. In some embodiments, an effective amount ranges from about 0.001  
15 mg/kg to about 500 mg/kg body weight of the subject. In some embodiments, the effective amount of the agent ranges from about 0.05 mg/kg to about 30 mg/kg, from about 0.1 mg/kg to about 30 mg/kg, from about 1 mg/kg to about 25 mg/kg, from about 1 mg/kg to about 20 mg/kg, or from about 1 or 2 mg/kg to about 15 mg/kg.

20 [0061] The agents, *e.g.*, AC, of the present invention can be administered at various times. Ceramidase, *e.g.*, AC, is administered prior to the onset of infection in some embodiments. In other embodiments, the ceramidase, *e.g.*, AC, is administered after the onset of infection. Further still, the ceramidase, *e.g.*, AC, may be administered prior to and after the onset of infection according to some  
25 embodiments of the present invention.

[0062] Another aspect of the present invention relates to methods of monitoring the effectiveness of a therapy in a subject having a pathogenic infection and an underlying disease condition. The method includes selecting a subject, providing a baseline ceramide level in a bodily fluid sample from the  
30 selected subject before the therapy, and treating the pathogenic infection with the therapy, which, for example, can be the therapeutic administration of a ceramidase

such as, *e.g.*, AC. The method further includes detecting a post-therapy ceramide level in a bodily fluid sample from the selected subject following the therapy, comparing the baseline ceramide level with the post-therapy ceramidase level, and identifying whether the therapy has been effective based on the comparing and/or  
5 the pathology of the pathogenic infection.

[0063] In another aspect of the present invention, a kit or reagent system for using or administering the agents of the present invention. Such kits will contain a reagent combination including the particular elements required to conduct an assay according to the methods disclosed herein. The reagent system  
10 is presented in a commercially packaged form, as a composition or admixture where the compatibility of the reagents will allow, in a test device configuration, or more typically as a test kit, *i.e.*, a packaged combination of one or more containers, devices, or the like holding the necessary reagents, and preferably including written instructions for the performance of assays. The kit may be  
15 adapted for any configuration of an assay and may include compositions for performing any of the various assay formats described herein.

[0064] Reagents useful for the disclosed methods can be stored in solution or can be lyophilized. When lyophilized, some or all of the reagents can be readily stored in microtiter plate wells for easy use after reconstitution. It is  
20 contemplated that any method for lyophilizing reagents known in the art would be suitable for preparing dried down reagents useful for the disclosed methods.

[0065] Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present  
25 invention, unless specified.

## EXAMPLES

**Example 1 – Mice.**

[0066] B6.129P2(CF/3)-*Cftr*<sup>TgH(neoim)Hgu</sup> (“CF<sup>MHH</sup>”) congenic mice were produced through the inbreeding of the original *Cftr*<sup>TgH(neoim)Hgu</sup> mutant mouse, 5 which was generated by insertional mutagenesis in exon 10 of the *Cftr* gene. See Charizopoulou *et. al.*, “Instability Of The Insertional Mutation In *Cftr*<sup>TgH(neoim)Hgu</sup> Cystic Fibrosis Mouse Model,” *BMC Genet.* 5 p. 6 (2004), which is hereby incorporated by reference in its entirety. This congenic *Cftr*<sup>MHH</sup> strain was then backcrossed into the B6 background. These mice still express low levels of 10 CFTR, and can thus be fed a standard mouse diet. They exhibit normal development, but also display pulmonary pathology typical for CF. They are herein referred to as “CF” Mice. See Teichgräber *et. al.*, “Ceramide Accumulation Mediate Inflammation, Cell Death And Infection Susceptibility In Cystic Fibrosis,” *Nat Med.* 14(4), pp. 382-391 (2008); Wolbeling *et. al.*, “Head- 15 out Spirometry Accurately Monitors the Course of Pseudomonas aeruginosa Lung Infection in Mice,” *Respiration* 80:340-6 (2010), which is hereby incorporated by reference in its entirety. Syngenic B6 mice were used as controls.

[0067] For some experiments, *Cftr*<sup>tm1Unc</sup>-*Tg*<sup>(FABPCFTR)</sup> mice (“*Cftr*<sup>-/-</sup>”, 20 purchased from The Jackson Laboratory, Bar Harbor, ME) were backcrossed for more than 10 generations with C57BL/6 mice. The mice are completely deficient in *Cftr* in all organs except the intestine, where they express human CFTR which is under the control of a fatty acid binding protein (“FABP”) promoter. The transgene prevents intestinal obstruction and enables feeding with a normal diet. Again, B6 mice were used as controls. No major differences were observed in 25 experiments which employed both the *Cftr*<sup>-/-</sup> and *Cftr*<sup>MHH</sup> strains.

[0068] For other experiments, mice deficient in the enzyme ceramide synthase 2 were used. These mice (*CerS2*<sup>-/-</sup>) were generated by disruption of the first intron of the *CerS2* mouse gene. They do not live beyond ~16 months and accumulate C16 ceramide in most tissues (Pewzner-Jung *et al.*, “A Critical Role 30 of Ceramide Synthase 2 in Liver Homeostasis I. Alterations in The Lipid

Metabolic Pathway,” *J Biol. Chem.* 285:10902 (2010), which is hereby incorporated by reference in its entirety).

[0069] The mice were housed and bred within isolated cages in the vivarium of the University Hospital, University of Duisburg-Essen, Germany.

5 They were repeatedly evaluated for a panel of common murine pathogens according to the 2002 recommendations of the Federation of European Laboratory Animal Science Associations. The mice were free of all pathogens. Procedures performed on the animals were approved by the Bezirksregierung Duesseldorf, Duesseldorf, Germany.

#### 10 **Example 2 – Antibodies and Reagents.**

[0070] All ceramide stainings were performed using the monoclonal mouse anti-ceramide antibody clone S58-9 (Glycobiotech) that was visualized with Cy3-donkey-anti-mouse IgM F(ab)<sub>2</sub> fragments (Jackson #715-166-020) or Cy5-coupled donkey-anti-mouse-IgM antibody (Jackson #715-176-020).

15 Recombinant human acid ceramidase was produced in Chinese Hamster Ovary (“CHO”) cells and purified from the media as previously described. He *et al.*, *J Biol. Chem.* 278:32978-86 (2003), which is hereby incorporated by reference in its entirety.

#### **Example 3 – Bacteria.**

20 [0071] The laboratory strain American Type Culture Collection 27853 *P. aeruginosa* and the previously described clinical *P. aeruginosa* isolate (“762”) were used. Bacteria were plated from frozen stocks on fresh Tryptic Soy Agar plates (TSA; Becton Dickinson), grown at 37°C for 14-16 hours and resuspended in 40 mL of 37°C warmed Tryptic Soy Broth (Becton Dickinson) to an optic  
25 density of 0.225 at 550 nm. The bacterial suspension was then incubated at 37°C for 1 hr with 125 rpm shaking to attain bacteria in the early logarithmic growth phase. See Grassmé *et. al.*, “Host Defense Against *Pseudomonas aeruginosa* Requires Ceramide-Rich Membrane Rafts,” *Nat Med.* 9(3):322-330 (2003), which is hereby incorporated by reference in its entirety. Bacteria were then washed  
30 twice and resuspended in warmed RPMI-1640 medium (Invitrogen) supplemented

with 10 mM HEPES (RPMI+HEPES). The final concentration of bacteria was quantified by photospectrometry.

**Example 4 – *In Vivo* Immunohistochemistry.**

[0072] For immunohistochemical evaluation of murine bronchial epithelial  
5 cells, mice were sacrificed by cervical dislocation and immediately perfused *via*  
the right heart with ice cold normal saline for two minutes at low pressure. This  
was followed by cardiac perfusion with 4% PBS-buffered PFA for 10-15  
minutes. After this initial clearance of blood and fixation, the lungs were removed  
and further fixed in 4% PFA for 24-36 hrs. The tissue was serially dehydrated  
10 using an ethanol to xylol gradient and then embedded in paraffin.

[0073] The samples were then sectioned at 7  $\mu\text{m}$ , dewaxed, re-hydrated,  
and treated with Pepsin (Invitrogen) for 15 min at 37°C. They were then washed  
with water and PBS and blocked for 10 min at room temperature with PBS and  
0.05% Tween 20 (Sigma) and 1% FCS. The samples were then consecutively  
15 stained with primary antibodies in H/S +1% FCS at room temperature for 45 min.  
Samples were washed between the stainings twice with PBS + 0.05% Tween 20  
and once with PBS. The tissue was secondarily labeled with fluorescent-coupled  
secondary antibodies in H/S +1% FCS in the dark for 30 minutes. Tissue was  
again washed twice with PBS + 0.05% Tween 20, once with PBS and finally  
20 embedded in Mowiol. Samples were evaluated using a confocal microscope as  
described below.

**Example 5 – Inhalation and *In Vivo* Infection.**

[0074] *P. aeruginosa* was prepared as described above and resuspended in  
RPMI-1640 plus 10 mM HEPES to a final concentration of  $1 \times 10^8$  CFU in 20  $\mu\text{L}$   
25 medium. They were then inoculated using a plastic-coated 30-gauge needle,  
which was inserted 2 mm into the nose. Bacterial numbers were quantified in  
mouse lungs 2 hrs after infection. Mice were sacrificed and the lungs were  
removed, homogenized, and lysed in 5 mg/mL Saponin to release intracellular  
bacteria. The samples were then washed in sterile PBS, diluted, and plated in  
30 duplicate on TSA plates for 12 hours. Bacterial numbers were counted and

represent the number of the bacteria in whole lung samples. This mode of infection more accurately evaluates mucociliary clearance than other pulmonary infection models, such as intratracheal infection. See Teichgräber *et. al.*, “Ceramide Accumulation Mediate Inflammation, Cell Death And Infection Susceptibility In Cystic Fibrosis,” *Nat Med.* 14(4):382-391 (2008); Zhang *et. al.*, “Kinase Suppressor Of Ras-1 Protects Against Pulmonary *Pseudomonas aeruginosa* Infections,” *Nat Med.* 17(3):341-346 (2011), which are hereby incorporated by reference in their entirety.

#### **Example 6 – Statistics.**

10 [0075] Data are expressed as arithmetic means  $\pm$  SD and performed statistical analysis as indicated. Since all values were normally distributed, one-way ANOVA was applied. Significances are indicated in the figures with asterisks.

#### **Example 7 – Confocal Microscopy and Discussion.**

15 [0076] Samples were examined with a Leica TCS-SP5 confocal microscope equipped with a 100x oil emersion lens, and images were analyzed with Leica LCS software (Leica Microsystems). All comparative samples were measured with identical settings.

[0077] Ceramide is increased in the lungs of CF subjects and mice (Figure 20 1A), and is an important factor in the susceptibility of CF mice to *P. aeruginosa* infection. See Grassmé *et. al.*, “CFTR-dependent Susceptibility Of The Cystic Fibrosis-Host To *Pseudomonas aeruginosa*,” *Int J Med Microbiol.* 300(8):578-83 (2010), which is hereby incorporated by reference in its entirety. Previous studies demonstrated that pharmacological inhibition of acid sphingomyelinase or genetic 25 heterozygosity of the acid sphingomyelinase gene are sufficient to normalize ceramide levels in mouse CF lungs. See Becker *et. al.*, “Acid Sphingomyelinase Inhibitors Normalize Pulmonary Ceramide And Inflammation In Cystic Fibrosis,” *Am J Respir Cell Mol Biol.* 42(6):716-24 (2010), which is hereby incorporated by reference in its entirety.

[0078] In addition, CF<sup>MHH</sup> *Cftr*-deficient mice inhaled acid ceramidase, which hydrolyzes ceramide. This inhalation corrected ceramide levels in the bronchial epithelial cells of CF mice (Figure 1B). Inhalation of the solvent, *i.e.*, 0.9% NaCl did not affect ceramide levels.

5 [0079] In another example, *Cftr*<sup>-/-</sup>, *CerS2* or normal mice were inhaled with saline or acid ceramidase and then infected with *P. aeruginosa* (Figure 2). CF<sup>MHH</sup> *Cftr*-deficient and *CerS2* mice accumulate ceramide in their lungs relative to normal mice. Two hours after inhalation they were sacrificed and the remaining bacteria in the lungs was quantified. Wild-type mice cleared the *P.*  
10 *aeruginosa* effectively, whereas *Cftr*<sup>-/-</sup> or *CerS2*<sup>-/-</sup> mice inhaled with saline could not and had large numbers of remaining bacteria. In contrast, *Cftr*<sup>-/-</sup> or *CerS2*<sup>-/-</sup> mice inhaled with acid ceramidase had very low bacterial titers like normal mice.

[0080] The identification of irregularities in naive CF airways provides a novel concept for the prevention of infection in CF subjects. The present  
15 examples provide for several approaches to thwarting infection and treating the leading cause of death for subjects with CF.

#### **Example 8 – AC Inhalation Protects Against *Pseudomonas* Infections.**

[0081] Mice were inhaled with 100 micrograms of recombinant acid ceramidase (AC) in 0.8 mL of 0.9% NaCl 30 to 45 minutes before intranasal  
20 infection with  $1 \times 10^8$  colony-forming units (CFU) of *P. aeruginosa* strain 762 or ATCC 27853. The lungs were removed 4 hours after infection, homogenized, lysed in 5 mg/mL saponin for 10 minutes, and washed. Aliquots were plated on LB plates and allowed to grow overnight. CFUs on the LB plates were counted to determine the number of *P. aeruginosa* bacteria in the lung. Shown are means  $\pm$   
25 standard deviation of four independent experiments.

[0082] A single inhalation of AC prevented infection of CF mice with two different strains of *P. aeruginosa* (Figure 3). Clinical strain 762 was originally obtained from a urinary tract infection, while strain ATCC 27853 is a laboratory strain. Inhalation of saline alone was used as a control.

[0083] CF mice were inhaled with recombinant acid ceramidase (100 micrograms in 0.8 mL of 0.9% NaCl). Saline was used as a control. In all cases, mice were inhaled 30-45 minutes before inhalation with clinical *Pseudomonas aeruginosa* strain 762, and then sacrificed 4 hours after. The lungs were removed  
5 4 hours after infection, homogenized, lysed in 5 mg/mL saponin for 10 minutes, and washed. Aliquots were plated on LB plates and allowed to grow overnight. CFUs on the LB plates were counted to determine the number of *P. aeruginosa* bacteria in the lung.

[0084] Inhalation of CF mice with recombinant acid ceramidase prevented  
10 infection with clinical strain 762 *P. aeruginosa* to a similar degree (Figure 3).

[0085] Although preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, and the like can be made without departing from the spirit of the invention and these are, therefore, considered to be within  
15 the scope of the invention as defined in the claims which follow.


**WHAT IS CLAIMED:**

1. A method for treating or preventing pathogenic infections in a subject having Cystic Fibrosis, COPD, and/or an open wound, said method comprising:
  - 5 selecting a subject having Cystic Fibrosis, COPD, and/or an open wound and  
administering to said selected subject a ceramidase under conditions effective reduce ceramide and to treat or prevent said pathogenic infection in said selected subject.
- 10 2. The method of claim 1, wherein the subject is selected based on elevated ceramide levels compared to a reference level for a subject not having said Cystic Fibrosis, COPD, and/or an open wound.
3. The method of claim 1, wherein said selecting is based on ceramide level in lung epithelium, nasal epithelium, mucus, and/or cells isolated  
15 from an open wound site.
4. The method of claim 1, wherein said administering is carried out under conditions effective to normalize ceramide levels in the subjects' respiratory epithelia, mucus, or cells at an open wound site.
5. The method of claim 1, wherein said ceramidase is acid  
20 ceramidase.
6. The method of claim 1, wherein one or more additional agents that reduce ceramide levels are administered in combination with said ceramidase.
7. The method of claim 6, wherein said one or more additional  
25 agents are selected from the group consisting of one or more additional ceramide reducing agents, one or more acid sphingomyelinase inhibitors, one or more agents to reduce infection, and combinations thereof.


8. The method of claim 7, wherein said one or more additional agents is one or more agents to reduce infection and is selected from the group consisting of antibiotics, reagents that block binding of pathogens to lung epithelium, reagents to reduce mucus viscosity, chaperone reagents to enhance  
5 missing protein function, and combinations thereof.
9. The method of claim 7, wherein said ceramidase is administered simultaneously, separately, or sequentially with said one or more additional agents.
10. The method of claim 1, wherein said administering is oral,  
10 topical, intranasal, intraperitoneal, intravenous, subcutaneous, or by aerosol inhalation.
11. The method of claim 10, wherein said administering is by aerosol inhalation.
12. The method of claim 1, wherein the ceramidase is  
15 administered in amount from 0.001 mg/kg to 500 mg/kg.
13. The method of claim 1, wherein said pathogenic infection is a viral, fungal, prionic, or bacterial infection.
14. The method of claim 13, wherein said pathogenic infection is a *Pseudomonas* infection.
- 20 15. The method of claim 14, wherein said *Pseudomonas* infection is a *Pseudomonas aeruginosa* infection.
16. The method of claim 1, wherein said ceramidase is administered prior to onset of infection.
17. The method of claim 1, wherein said ceramidase is  
25 administered after onset of infection.
18. The method of claim 1, wherein the selected subject has Cystic Fibrosis.


19. The method of claim 1, wherein the selected subject has COPD.

20. The method of claim 1, wherein the selected subject has an open wound.



**FIGURES 1A-1B**

**FIGURE 2**



**FIGURE 3**

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US13/43608

<p><b>A. CLASSIFICATION OF SUBJECT MATTER</b>                  IPC(8) - A61M 11/00; A61P 31/00 (2013.01)                  USPC - 128/200.14; 424/130.1                  According to International Patent Classification (IPC) or to both national classification and IPC</p>														
<p><b>B. FIELDS SEARCHED</b></p> <p>Minimum documentation searched (classification system followed by classification symbols)                  IPC(8): A61M 11/00; A61P 31/00 (2013.01)                  USPC: 128/200.14; 424/130.1</p> <p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p> <p>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)                  MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); Google Scholar; IP.com; DialogPRO; treat*, prescrib*, Cure, cured, curing, cures, mitigate*, cystic NEAR2 fibrosis, CF, COPD, Chronic NEAR2 obstructive NEAR2 pulmonary NEAR2 disease, Wound*, Lacerat*, Cut, cuts, trauma, administ*, give*, inhal*, appl*, Ceramidase</p>														
<p><b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b></p> <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>Y</td> <td>US 2010/0285139 A1 (GULBINS, E) November 11, 2010; abstract; paragraphs [0022], [0023], [0038], [0042], [0053], [0059], [0068], [0109]</td> <td>1-20</td> </tr> <tr> <td>Y</td> <td>US 2008/0199450 A1 (SCHUCHMAN, EH et al.) August 21, 2008; abstract; paragraphs [0008], [0015], [0061]</td> <td>1-20</td> </tr> <tr> <td>Y</td> <td>WO 2007/136635 A1 (NORRIS, J et al.) November 29, 2007; page 41, lines 28-31; page 57, lines 1-4</td> <td>19</td> </tr> </tbody> </table>			Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	Y	US 2010/0285139 A1 (GULBINS, E) November 11, 2010; abstract; paragraphs [0022], [0023], [0038], [0042], [0053], [0059], [0068], [0109]	1-20	Y	US 2008/0199450 A1 (SCHUCHMAN, EH et al.) August 21, 2008; abstract; paragraphs [0008], [0015], [0061]	1-20	Y	WO 2007/136635 A1 (NORRIS, J et al.) November 29, 2007; page 41, lines 28-31; page 57, lines 1-4	19
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.												
Y	US 2010/0285139 A1 (GULBINS, E) November 11, 2010; abstract; paragraphs [0022], [0023], [0038], [0042], [0053], [0059], [0068], [0109]	1-20												
Y	US 2008/0199450 A1 (SCHUCHMAN, EH et al.) August 21, 2008; abstract; paragraphs [0008], [0015], [0061]	1-20												
Y	WO 2007/136635 A1 (NORRIS, J et al.) November 29, 2007; page 41, lines 28-31; page 57, lines 1-4	19												
<p><input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/></p>														
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>“A” document defining the general state of the art which is not considered to be of particular relevance</td> <td>“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>“E” earlier application or patent but published on or after the international filing date</td> <td>“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>“O” document referring to an oral disclosure, use, exhibition or other means</td> <td>“&amp;” document member of the same patent family</td> </tr> <tr> <td>“P” document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table>			“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family	“P” document published prior to the international filing date but later than the priority date claimed			
“A” document defining the general state of the art which is not considered to be of particular relevance	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention													
“E” earlier application or patent but published on or after the international filing date	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone													
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art													
“O” document referring to an oral disclosure, use, exhibition or other means	“&” document member of the same patent family													
“P” document published prior to the international filing date but later than the priority date claimed														
<p>Date of the actual completion of the international search</p> <p>10 October 2013 (10.10.2013)</p>		<p>Date of mailing of the international search report</p> <p><b>21 OCT 2013</b></p>												
<p>Name and mailing address of the ISA/US</p> <p>Mail Stop PCT, Attn: ISA/US, Commissioner for Patents                  P.O. Box 1450, Alexandria, Virginia 22313-1450                  Facsimile No. 571-273-3201</p>		<p>Authorized officer:</p> <p>Shane Thomas</p> <p>PCT Helpdesk: 571-272-4300                  PCT OSP: 571-272-7774</p>												